Poxel announces PXL770 awarded FDA fast track designation for X-linked adrenoleukodystrophy

11 April 2022 - Poxel is pleased to announce that the U.S. FDA has granted fast track designation to PXL770 ...

Read more →

Spectrum Pharmaceuticals announces FDA acceptance of BLA resubmission for eflapegrastim

11 April 2022 - FDA has assigned 9 September 2022 as the PDUFA date. ...

Read more →

Hugel says FDA’s complete response letter will not affect Letybo approval

11 April 2022 - Hugel said a complete response letter from the U.S. FDA on botulinum toxin Letybo requires supplementary ...

Read more →

Alzheimer's drug makers seek accelerated FDA review despite U.S. coverage decision

8 April 2022 - Eisai and Eli Lilly on Friday said they still plan to seek accelerated U.S. approval for ...

Read more →

Amphastar receives FDA approval for ganirelix acetate injection

8 April 2022 - Amphastar Pharmaceuticals announced that the U.S. FDA has approved the Company's abbreviated new drug application for ganirelix ...

Read more →

‘Precedents are important’: Aduhelm coverage restrictions could shape the future of accelerated approval

9 April 2022 - Whither accelerated approval? ...

Read more →

Joint statement from CMS Administrator Chiquita Brooks-LaSure and FDA Commissioner Robert M. Califf on ensuring access to safe and effective treatments

8 April 2022 - Ensuring the availability of innovative interventions for people is a shared priority for both the CMS and ...

Read more →

Clayton Pharmaceuticals and VistaPharm receive FDA approval for sucralfate oral suspension

7 April 2022 - Approval validates the use of novel pathway for bioequivalence of complex generic drug products, which increases ...

Read more →

Some hoped FDA approval of Pfizer's COVID vaccine would convince unvaccinated Americans. It didn't, study finds.

6 April 2022 - After the Food and Drug Administration approved Pfizer-BioNTech’s COVID-19 vaccine in August, public health experts were ...

Read more →

U.S. FDA aims to decide on strain selection for COVID boosters by June

6 April 2022 - The U.S. FDA said it is aiming to come up with a decision on coronavirus strain ...

Read more →

BioXcel Therapeutics announces FDA approval of Igalmi (dexmedetomidine) sublingual film for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults

6 April 2022 - U.S. commercial launch planned for Q2 2022. ...

Read more →

Dialectic Therapeutics announces DT2216 has received fast track designation from the FDA for adult patients with relapsed or refractory peripheral and cutaneous T-cell lymphoma

5 April 2022 - Dialectic Therapeutics today announced that the U.S. FDA has granted fast track designation to DT2216 for adult ...

Read more →

FDA approves Novartis Vijoice (alpelisib) as first and only treatment for select patients with PIK3CA related overgrowth spectrum

6 April 2022 - Approval based on real world data from EPIK-P1 study, which showed patients treated with Vijoice experienced reduction ...

Read more →

Curium announces FDA approval of a generic version of DaTscan (Ioflupane I 123 injection) in the U.S.

5 April 2022 - Curium announced today that its generic version of DaTscan (Ioflupane I 123 injection) was approved on 30 ...

Read more →

FDA updates sotrovimab emergency use authorisation

 5 April 2022 - Sotrovimab is no longer authorised to treat COVID-19 in any U.S. region due to increases in ...

Read more →